IP Library Granted Patent US 8,563,725
Granted Patent B2
US 8,563,725 · App. 13/093,892 · Granted Oct 22, 2013

Preparation of saturated ketone morphinan compounds having low metal content

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,725
App. No.
13/093,892
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention provides processes for the preparation of saturated ketone morphinan compounds from a morphinan comprising an allyl alcohol ring moiety, wherein the final product has a low metal content. In particular, the invention provides processes that utilize isomerization reactions catalyzed by transition metal catalysts and the subsequent removal of the transition metal using metal scavengers.

Claims (24)

1. A process for preparing a compound having Formula (II), wherein the compound having Formula (II) is substantially metal-free:

the process comprising:

a) contacting a compound having Formula (I) with a transition metal catalyst to form a reaction product comprising the compound having Formula (II); and

b) contacting the reaction product of step (a) with a metal scavenger such that the metal scavenger binds the transition metal catalyst, thereby yielding the substantially metal-free compound having Formula (II), the compound of Formula (I) being:

wherein:

A is oxygen;

R 1 , R 2 , and R 3 are independently chosen from hydrogen, halogen, hydroxy, protected hydroxy, {—}SH, {—}SR 1611 , {—}OR 1611 , and {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl;

R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 14 , R 15a , R 15b , R 16a , R 16b , and R 17 are independently chosen from hydrogen, halogen, hydroxy, {—}SH, {—}SR 1611 , {—}OR 1611 , and {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl; provided that any of R 10a and R 10b , R 15a and R 15b , and R 16a and R 16b may together form a moiety selected from the group consisting of {═}O, {═}S, and {═}NR 1613 ; and

R 1611 , R 1612 , an R 1613 are independently chosen from hydrocarbyl, and substituted hydrocarbyl.

2. The process of claim 1 , wherein R 1 , R 2 , R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 15a , R 15b , R 16a , and R 16b are hydrogen; R 3 is chosen from hydroxy, protected hydroxy, alkyloxy, and acyloxy; R 14 is hydrogen or hydroxy; and R 17 is chosen from hydrogen, alkyl, cycloalkyl, cycloalkylmethyl, allyl, and aryl.

3. The process of claim 2 , wherein R 3 is hydroxy or methyoxy; R 14 is hydrogen; and R 17 is methyl.

4. The process of claim 1 , wherein the transition metal catalyst is chosen from a transition metal element, a transition metal salt, and a transition metal complex; and comprises a transition metal chosen from iridium, nickel, osmium, palladium, platinum, rhodium, and ruthenium.

5. The process of claim 4 , wherein the transition metal salt comprises an anion chosen from an acetate, an acetyacetonate, an alkoxide, a butyrate, a carbonyl, a dioxide, a halide, a hexonate, a hydride, a mesylate, an octanate, a nitrate, a nitrosyl halide, a nitrosyl nitrate, a sulfate, a sulfide, a sulfonate, a phosphate, a trifluoromethanesulfonate, a trimethylacetate, a tosylate, and combinations thereof.

6. The process of claim 4 , wherein the transition metal complex is chosen from a bis(allyl)-ruthenium complex selected from {Ru(η 3 :η 3 -C 10 H 16 )(μ-Cl)Cl} 2 , Ru(η 3 :η 2 :η 3 -C 12 H 18 )Cl 2 , and {Ru(η 3 :η 3 -C 12 H 20 )(μ-Cl)Cl} 2 ; and a phosphine complex selected form (phosphine) x PdCl 2 , (PPh 3 ) 4 Pd, RuCl 2 (PPh 3 ) 3 , RuCl 2 (PPh 3 ) 4 , RuH 2 (PPh 3 ) 4 , and RhCl(PPh 3 ) 3 .

7. The process of claim 1 , wherein the weight ratio of the compound having Formula (I) to the transition metal catalyst is from about 1:0.0001 to about 1:0.1; and the weight ratio of the compound having Formula (I) to the metal scavenger is from about 1:0.005 to about 1:0.5.

8. The process of claim 1 , wherein the metal scavenger comprises a functional group chosen from acetyl, amide, amine, amino, guanidine, imidazole, imine, mercaptophenyl, phosphonic acid, trimercaptotriazine, triamine, thiol, thiourea, and combinations thereof.

9. The process of claim 1 , wherein steps (a) and (b) are conducted in the presence of a protic or an aprotic solvent; steps (a) and (b) are conducted at a temperature from about 10° C. to about 120° C.; and step (b) is conducted at a pH from about 0 to about 7.

10. The process of claim 1 , wherein the process is a one-pot synthesis.

11. The process of claim 1 , wherein the substantially metal-free compound of Formula (II) has a metal content of less than about 100 ppm.

12. The process of claim 1 , wherein the optical activity of the compounds having Formulas (I) and (II) is (−) or (+), and the configuration of C-5, C-13, C-14, and C-9, respectively, is selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS, provided that the C-15 and the C-16 carbons are both either on the alpha face of the molecule or the beta face of the molecule.

13. The process of claim 1 , wherein the process is a one-pot synthesis; the transition metal catalyst is chosen from a transition metal element, a transition metal salt, and a transition metal complex; the metal of the transition metal catalyst is chosen from iridium, nickel, osmium, palladium, platinum, rhodium, and ruthenium; the weight ratio of the compound having Formula (I) to the transition metal catalyst is from about 1:0.0001 to about 1:0.1; the metal scavenger comprises a functional group chosen from acetyl, amide, amine, amino, guanidine, imidazole, imine, mercaptophenyl, phosphonic acid, trimercaptotriazine, triamine, thiol, thiourea, and combinations thereof; the weight ratio of the compound having Formula (I) to the metal scavenger is from about 1:0.005 to about 1:0.5; steps (a) and (b) are conducted in the presence of a protic solvent and at a temperature from about 10° C. to about 120° C.; the weight ratio of the protic solvent to the compound having Formula (I) is from about 0.5:1 to about 20:1; step (b) of the process is conducted at a pH from about 0 to about 7; the compound having Formula (II) is separated from the metal scavenger by filtration after step (b); the compound having Formula (II) has a yield of at least about 60%; and the compound having Formula (II) has a metal content of less than about 100 ppm.

14. The process of claim 13 , wherein the optical activity of the compounds having Formulas (I) and (II) is (−) or (+), and the configuration of C-5, C-13, C-14, and C-9, respectively, is selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS, provided that the C-15 and the C-16 carbons are both either on the alpha face of the molecule or the beta face of the molecule.

15. The process of claim 3 , wherein the process is a one-pot synthesis; the transition metal catalyst is a bis(allyl)-ruthenium complex; the weight ratio of the compound having Formula (I) to the bis(allyl)-ruthenium complex is from about 1:0.001 to about 1:0.05; step (a) of the process is conducted in the presence of a protic solvent comprising ethanol and water and at a temperature from about 65° C. to about 90° C.; the weight ratio of the protic solvent to the compound having Formula (I) is about 1:1 to about 10:1; the metal scavenger has a thiol functional group and is attached to a silica-based solid phase; the weight ratio of the compound having Formula (I) to the metal scavenger is about 1:0.02 to about 1:0.1; step (b) of the process is conducted in the presence of a protic solvent comprising ethanol and water, at a pH from about 2 to about 3, and at a temperature from about 60° C. to about 105° C.; the compound having Formula (II) is separated from the metal scavenger by filtration after step (b); the compound having Formula (II) has a yield of at least about 80%; and the compound having Formula (II) has a metal content of less than about 50 ppm.

16. The process of claim 15 , wherein the optical activity of the compounds having Formulas (I) and (II) is (−) or (+), and the configuration of C-5, C-13, C-14, and C-9, respectively, is selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS, provided that the C-15 and the C-16 carbons are both either on the alpha face of the molecule or the beta face of the molecule.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Dec 9, 2013
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 031771/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2011
From: JIANG, TAO; WANG, PETER X.; BERBERICH, DAVID W.
To: MALLINCKRODT INC.
Reel/Frame 026179/0465 →